Year 2019

Time To Put A Stop To The Abuse Of Orphan Drug Regulation- The Latest Scandal

Ellen 't Hoen writes: Today, the Dutch Medical Journal (Nederlands Tijdschrift voor Geneeskunde) reported on the case of lutetium-octreotaat, a cancer drug developed by researchers in the Dutch Erasmus medical centre in Rotterdam. For the last 18 years, the hospital pharmacy made the medicine to treat their patients, keeping prices relatively low. But now the drug is being marketed by Swiss pharmaceutical giant Novartis, and its price has skyrocketed to Euro 23,000 an infusion from an original price of Euro 4,000 an infusion.

What’s The Cost Of Allowing Patent Theft? Don’t Wait To Find Out

Russ Genet writes: Protecting patents can be expensive, especially for companies competing in a global arena where aggressive startups, cut-rate competitors and industrial giants are all vying for the next big innovation to snatch up or move to market. However, failing to protect patents can be equally expensive. It is estimated that patent theft costs the US economy billions each year. And for the corporate patent owner, failing to defend patent rights today can significantly limit their value in the future.